INVESTOR RELATIONS
CEO comment
January 24, 2025 – Greetings from ASCO-GI 2025 >>
November 12, 2024
“With a solid evidence platform and supported by strong partnerships, we put the final pieces of the puzzle into place during the third quarter for the design of the clinical study that will evaluate our drug candidate arfolitixorin as a new potential component in the treatment of colorectal cancer. Few drug candidates in the clinical development phase that we are in have as broad a scientific base as arfolitixorin – and all new data, from preclinical studies to analyses of the previous phase III study AGENT, indicate that the new study design offers greater possibilities for arfolitixorin to demonstrate its full potential,“ says CEO, Petter Segelman Lindqvist.
INVESTORS – latest reports and presentations
Media – Lates pressreleases
Isofol appoints Roger Tell as Chief Medical Officer ahead of initiation of clinical study
GOTHENBURG, Sweden, February 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roger Tell has been appointed Chief Medical Officer…
Isofol announces the presentation of a post-hoc analysis of the phase III study AGENT at the 2025 ASCO GI symposium
GOTHENBURG, Sweden, January 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that an abstract of the post-hoc per-protocol analysis of…
Isofol and its partner Solasia plan to expand the upcoming clinical trial of arfolitixorin to Japan
GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that its partner Solasia Pharma K.K. (Solasia) has made…

SEE HOW ARFOLITIXORIN
WORKS IN CANCER CELLS
About arfolitixorin
Want to know more about the the drug candidate arfolitxorin?
Last updated 01-30-2025